Debevoise & Plimpton LLP is advising The Carlyle Group (NASDAQ: CG), as MedRisk’s current controlling shareholder, in the sale of a majority stake in MedRisk to CVC Capital Partners. Carlyle will retain a significant minority investment in the company and will control it jointly with CVC. For more information, please see the companies’ press release. Read More>

Debevoise & Plimpton LLP has advised PSG in the formation of its first European-focused fund, PSG Europe, a €1.25 billion fund that will mirror the firm’s existing buy and build strategy in the U.S., which partners with lower middle-market software and technology-enabled service companies. The final close of PSG Europe brings PSG’s aggregate capital commitments across Europe and the U.S. to more than $5 billion. For more information, please see PSG’s press release. Read More>

Debevoise & Plimpton LLP has advised Ant Group in its binding agreements with Mail.ru Group, USM, Russian Direct Investment Fund (RDIF) and MegaFon to create a payments joint venture (PJV) and a financial services joint venture (FSJV). Read More>

Debevoise & Plimpton LLP has advised Clayton, Dubilier & Rice (“CD&R”) in the formation of Clayton, Dubilier & Rice Fund XI, an approximately $16 billion fund, which is CD&R’s largest fund to date. Read More>

Debevoise & Plimpton LLP advised Antares Holdings LP (Antares) in its offering of $500 million aggregate principal amount of 3.95% notes due 2026. Read More>